ATE247652T1 - 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden - Google Patents
4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor ligandenInfo
- Publication number
- ATE247652T1 ATE247652T1 AT00919753T AT00919753T ATE247652T1 AT E247652 T1 ATE247652 T1 AT E247652T1 AT 00919753 T AT00919753 T AT 00919753T AT 00919753 T AT00919753 T AT 00919753T AT E247652 T1 ATE247652 T1 AT E247652T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- gaba
- receptors
- receptor ligands
- quinoline derivatives
- Prior art date
Links
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 title abstract 3
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 title abstract 3
- -1 4-SUBSTITUTED QUINOLINE Chemical class 0.000 title 1
- 102000004300 GABA-A Receptors Human genes 0.000 title 1
- 108090000839 GABA-A Receptors Proteins 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 102000027484 GABAA receptors Human genes 0.000 abstract 2
- 108091008681 GABAA receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12692699P | 1999-03-29 | 1999-03-29 | |
| PCT/US2000/008205 WO2000058303A1 (en) | 1999-03-29 | 2000-03-28 | 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE247652T1 true ATE247652T1 (de) | 2003-09-15 |
Family
ID=22427414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00919753T ATE247652T1 (de) | 1999-03-29 | 2000-03-28 | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6413982B1 (de) |
| EP (1) | EP1165542B1 (de) |
| JP (1) | JP2002540203A (de) |
| AT (1) | ATE247652T1 (de) |
| AU (2) | AU4038600A (de) |
| CA (1) | CA2368455A1 (de) |
| DE (1) | DE60004654T2 (de) |
| WO (2) | WO2000058303A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1165542B1 (de) | 1999-03-29 | 2003-08-20 | Neurogen Corporation | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
| CA2388593A1 (en) | 1999-11-12 | 2001-05-17 | Neurogen Corporation | Bicyclic and tricyclic heteroaromatic compounds |
| GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| NZ535239A (en) | 2002-03-27 | 2008-03-28 | Glaxo Group Ltd | Quinoline derivatives and their use as 5-HT6 ligands |
| GB0226462D0 (en) * | 2002-11-13 | 2002-12-18 | Merck Sharp & Dohme | Therapeutic agents |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| PL1558582T3 (pl) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem |
| WO2005066137A1 (en) * | 2003-12-19 | 2005-07-21 | Neurogen Corporation | 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases |
| WO2005061462A2 (en) * | 2003-12-19 | 2005-07-07 | Neurogen Corporation | Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators |
| US20050277639A1 (en) * | 2004-03-02 | 2005-12-15 | Phil Skolnick | 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones |
| WO2005099680A2 (en) | 2004-04-12 | 2005-10-27 | United Therapeutics, Inc. | Use of treprostinil to treat neuropathic diabetic foot ulcers |
| WO2005116009A1 (en) | 2004-05-18 | 2005-12-08 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors |
| ES2392905T3 (es) * | 2007-06-18 | 2012-12-14 | Richter Gedeon Nyrt. | Derivados de sulfonil-quinolina |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| US7863295B2 (en) * | 2008-02-12 | 2011-01-04 | Children's Medical Center Corporation | Treatments for neuropathy |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| HK1245660A1 (zh) | 2015-06-12 | 2018-08-31 | Axovant Sciences Gmbh | 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物 |
| TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物 |
| PL3920912T3 (pl) | 2019-02-04 | 2025-11-12 | Genzyme Corporation | Leczenie ciliopatii przy użyciu inhibitorów syntazy glukozyloceramidowej (gcs) |
| BR112022024413A2 (pt) * | 2020-06-10 | 2023-02-07 | Bayer Ag | Heterociclos substituídos com azabiciclila como fungicidas inovadores |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
| EP0940391B1 (de) | 1994-05-27 | 2004-08-18 | GlaxoSmithKline S.p.A. | Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten |
| IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
| EP0799225A4 (de) | 1994-12-23 | 1998-03-25 | Smithkline Beecham Corp | Verbindungen und verfahren |
| AR004735A1 (es) | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
| ES2236757T3 (es) | 1995-11-24 | 2005-07-16 | Glaxosmithkline S.P.A. | Derivados de quinolina. |
| GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| GB9524137D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| US5792766A (en) | 1996-03-13 | 1998-08-11 | Neurogen Corporation | Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands |
| EP0983262B1 (de) | 1997-05-23 | 2003-07-09 | GlaxoSmithKline S.p.A. | Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten |
| AP1201A (en) | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
| US6228868B1 (en) * | 1998-07-27 | 2001-05-08 | Abbott Laboratories | Oxazoline antiproliferative agents |
| EP1165542B1 (de) | 1999-03-29 | 2003-08-20 | Neurogen Corporation | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
-
2000
- 2000-03-28 EP EP00919753A patent/EP1165542B1/de not_active Expired - Lifetime
- 2000-03-28 AU AU40386/00A patent/AU4038600A/en not_active Abandoned
- 2000-03-28 WO PCT/US2000/008205 patent/WO2000058303A1/en not_active Ceased
- 2000-03-28 AT AT00919753T patent/ATE247652T1/de not_active IP Right Cessation
- 2000-03-28 CA CA002368455A patent/CA2368455A1/en not_active Abandoned
- 2000-03-28 JP JP2000608005A patent/JP2002540203A/ja active Pending
- 2000-03-28 DE DE60004654T patent/DE60004654T2/de not_active Expired - Fee Related
- 2000-03-28 US US09/536,922 patent/US6413982B1/en not_active Expired - Fee Related
- 2000-03-28 AU AU40380/00A patent/AU4038000A/en not_active Abandoned
- 2000-03-28 WO PCT/US2000/008196 patent/WO2000058313A1/en not_active Ceased
-
2002
- 2002-05-07 US US10/140,693 patent/US6624175B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60004654D1 (de) | 2003-09-25 |
| JP2002540203A (ja) | 2002-11-26 |
| WO2000058303A1 (en) | 2000-10-05 |
| WO2000058303A9 (en) | 2002-12-19 |
| EP1165542B1 (de) | 2003-08-20 |
| CA2368455A1 (en) | 2000-10-05 |
| WO2000058313A1 (en) | 2000-10-05 |
| AU4038600A (en) | 2000-10-16 |
| US20020198232A1 (en) | 2002-12-26 |
| US6624175B2 (en) | 2003-09-23 |
| DE60004654T2 (de) | 2004-06-24 |
| EP1165542A1 (de) | 2002-01-02 |
| AU4038000A (en) | 2000-10-16 |
| US6413982B1 (en) | 2002-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE247652T1 (de) | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden | |
| AP1503A (en) | Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors | |
| DE60231341D1 (de) | Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten | |
| BRPI0418112A (pt) | inibidores de p-38 quinase bicìclico heterocìclicos | |
| ATE347553T1 (de) | Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine | |
| NO20070347L (no) | Modulatorer av alfa7 nikotinske acetylkolinreseptorer og terapeutiske anvendelser | |
| MXPA04000372A (es) | Compuesto biciclicos de heteroarilo fusionados sustituidos con heteroarilo como ligandos del receptor gabaa. | |
| ATE293448T1 (de) | Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten | |
| MA29140B1 (fr) | Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10 | |
| ATE466014T1 (de) | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren | |
| ATE304533T1 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
| ATE342253T1 (de) | Azabicycloderivate als antagonisten des muscarinischen rezeptors | |
| MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
| PL1716152T3 (pl) | Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych | |
| NO306779B1 (no) | Naftalamider, anvendelse derav og farmasöytisk preparat | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| ATE428694T1 (de) | N-ä1h-indol-5-ylünaphthalin-1-sulphonamid- derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems | |
| DE60309852D1 (de) | Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden | |
| TW200624432A (en) | Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto | |
| MA29643B1 (fr) | Benzocycloheptapyridines comme inhibiteurs du recepteur tyrozine kinase met | |
| EA200501593A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
| DE60327375D1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| DE60313898D1 (de) | Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten | |
| MXPA04000023A (es) | Derivados de acido cicloalquilpirrol-3-carboxilico y derivados de acido heterocicloalquilpirrol-3-carboxilico como ligandos de receptor gabaa. | |
| MA29694B1 (fr) | Derives de l'imidazopyridine comme ligands du recepteur cannabinoide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1165542 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |